Morgan Stanley’s Biote Corp BTMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$291K Sell
153,907
-34,293
-18% -$70.7K ﹤0.01% 5791
2026
Q1
$254K Sell
188,200
-51,536
-21% -$104K ﹤0.01% 5776
2025
Q4
$623K Buy
239,736
+56,841
+31% +$155K ﹤0.01% 5405
2025
Q3
$549K Sell
182,895
-37,787
-17% -$135K ﹤0.01% 5464
2025
Q2
$887K Buy
220,682
+103,140
+88% +$381K ﹤0.01% 5163
2025
Q1
$391K Buy
117,542
+14,876
+14% +$71K ﹤0.01% 5438
2024
Q4
$634K Sell
102,666
-36,967
-26% -$215K ﹤0.01% 5323
2024
Q3
$779K Buy
139,633
+40,707
+41% +$272K ﹤0.01% 5183
2024
Q2
$739K Buy
98,926
+39,156
+66% +$242K ﹤0.01% 5126
2024
Q1
$347K Sell
59,770
-3,217
-5% -$16.1K ﹤0.01% 5483
2023
Q4
$311K Buy
62,987
+25,074
+66% +$129K ﹤0.01% 5532
2023
Q3
$194K Buy
37,913
+28,314
+295% +$167K ﹤0.01% 5585
2023
Q2
$64.9K Buy
+9,599
New +$56.9K ﹤0.01% 6118
2023
Q1
Sell
-5
Closed -$19 7723
2022
Q4
$19 Sell
5
-2,007
-100% -$8.39K ﹤0.01% 7773
2022
Q3
$9K Buy
2,012
+12
+0.6% +$51 ﹤0.01% 7096
2022
Q2
$8K Buy
+2,000
New +$15.7K ﹤0.01% 7265

Other funds holding BTMD

Morgan Stanley's BTMD Position: Q2 2026 in Review

Morgan Stanley reduced its Biote Corp (BTMD) stake by 18% in Q2 2026, selling an estimated $70.7K and leaving 153,907 shares worth $291K. The position accounts for ﹤0.01% of the portfolio, ranked #5791.

Morgan Stanley first reported a position in BTMD in Q2 2022 and has held it in 16 quarters since. The position peaked at $887K in Q2 2025. 71 funds tracked by Wall St. Rank hold BTMD as of Q2 2026.

  • Morgan Stanley held 153,907 shares of Biote Corp worth $291K as of Q2 2026.
  • Morgan Stanley sold 34,293 Biote Corp shares in Q2 2026, an estimated $70.7K.
  • Biote Corp made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5791 holding.
  • Morgan Stanley first reported a position in Biote Corp in Q2 2022 and has held it in 16 quarters since.
  • Morgan Stanley's Biote Corp position peaked at $887K in Q2 2025.
  • 71 funds tracked by Wall St. Rank held Biote Corp as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.